SCHEMBL9100653

SCHEMBL9100653

CN(F)C(=O)c1cccc(C(F)(F)F)c1

nearest known ligand 0.62

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CES2 O00748 2/20 0.62
ALDH1A1 P00352 2/20 0.59
OPRM1 P35372 1/20 0.56
OPRL1 P41146 1/20 0.56
NPSR1 Q6W5P4 1/20 0.54
SRD5A2 P31213 1/20 0.53
MEN1 O00255 2/20 0.51
KMT2A Q03164 2/20 0.51
POLB P06746 2/20 0.51
LMNA P02545 2/20 0.50
P2RX1 P51575 1/20 0.50
TP53 P04637 1/20 0.50
GPBAR1 Q8TDU6 1/20 0.49
GAA P10253 1/20 0.49
HTT P42858 1/20 0.49
RAB9A P51151 1/20 0.49
HPGD P15428 1/20 0.49
TAS1R3 Q7RTX0 1/20 0.48
TAS1R1 Q7RTX1 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3876454 0.88 CES2 (0.65) CES2ALDH1A1OPRM1OPRL1NPSR1
SCHEMBL20870672 0.88 CES2 (0.65) CES2ALDH1A1OPRM1OPRL1NPSR1
SCHEMBL25216553 0.85 CES2 (0.61) CES2ALDH1A1OPRM1OPRL1NPSR1
SCHEMBL13412203 0.82 NPSR1 (0.57) CES2ALDH1A1OPRM1OPRL1NPSR1
SCHEMBL323339 0.82 CES2 (0.57) CES2ALDH1A1OPRM1OPRL1NPSR1
SCHEMBL27721651 0.80 NPSR1 (0.59) CES2ALDH1A1OPRM1OPRL1NPSR1
SCHEMBL4245460 0.80 OPRM1 (0.64) CES2ALDH1A1OPRM1OPRL1NPSR1
SCHEMBL15933244 0.80 ALDH1A1 (0.56) CES2ALDH1A1OPRM1OPRL1NPSR1
SCHEMBL39834 0.78 CES2 (0.71) CES2ALDH1A1NPSR1SRD5A2MEN1
SCHEMBL30093723 0.78 CES2 (0.71) CES2ALDH1A1NPSR1SRD5A2MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130143858-A1 COMPOUNDS AND THEIR USE AS IKACH BLOCKERS ASTRAZENECA AB (SE) 2013-06-06 US disclosed
US-8361998-B2 Compounds and their use as IKACh blockers ASTRAZENECA AB 2013-01-29 US disclosed
WO-2012074469-A1 NEW IKACH BLOCKERS ASTRAZENECA AB (SE) 2012-06-07 WO disclosed
US-20120142659-A1 COMPOUNDS AND THEIR USE AS IKACH BLOCKERS ASTRAZENECA AB (SE) 2012-06-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130143858-A1 COMPOUNDS AND THEIR USE AS IKACH BLOCKERS KCNH2, KCNJ2, KCNH3 CES2 2329/4885ALDH1A1 2203/4885OPRM1 973/4885
US-20120142659-A1 COMPOUNDS AND THEIR USE AS IKACH BLOCKERS KCNH2, KCNJ2, KCNH3 CES2 2329/4885ALDH1A1 2203/4885OPRM1 973/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.